Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-05-27
2008-05-27
Canella, Karen A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S142100, C424S146100, C424S178100, C424S181100, C424S183100, C424S138100, C530S391100, C530S388800, C530S388210, C530S391300, C530S391700
Reexamination Certificate
active
10309762
ABSTRACT:
The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity of CA IX, in particular, tumors such as colorectal cancer, renal cell carcinoma (RCC), cervical and other cancers of epithelial origin.
REFERENCES:
patent: 5387676 (1995-02-01), Zavada et al.
patent: WO 88/08854 (1988-11-01), None
Paul (Fundamental Immunology, (textbook), 1993, pp. 292-293).
Abstract of Watanabe et al (Kawasaki Igakkaishi, 1997, vol. 23, pp. 241-249).
Opavsky et al (Genomics, 1996, vol. 33, pp. 480-487).
Lampman et al (Blood, 1989, vol. 74, pp. 262-269).
Chrastina, et al., “Biodistribution and pharmacokinetics of125l-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma”, Int. J. Cancer, vol. 105, pp. 873-881, (2003).
Chia, et al., “Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma”, Journal of Clinical Oncology, vol. 19, No. 16, pp. 3660-3668, (Aug. 15, 2001).
Knüppel-Ruppert, et al., “Immunochemical evidence for a unique GPI-anchored carbonic anhydrase isozyme in human cardiomyocytes”, American Journal Physiol. Heart Circ. Physiol., vol. 278, pp. H1335-H1344, (2000).
Swinson, et al., “Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer”, Journal of Clinical Oncology, vol. 21, No. 3, pp. 473-482, (Feb. 1, 2003).
Vermylen, et al., “Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma”, Eur. Respir. Journal, vol. 14, pp. 806-811, (1999).
Wykoff, et al., “Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast”, American Journal of Pathology, vol. 158, No. 3, pp. 1011-1019, (Mar. 2001).
Wykoff, et al., “Hypoxia-inducible expression of tumor-associated carbonic anhydrases”, Cancer Research, vol. 60, pp. 7075-7083, (Dec. 15, 2000).
International Search Report dated Sep. 16, 2003, for International Application No. PCT/US02/38550, filed Dec. 2, 2002.
Oosterwijk, et al., Monoclonal Antibody G 250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent From Normal Kidney,Int. J. Cancer, 38:489-494 (1986).
Oosterwijk, et al., Immunohistochemical Analysis of Monoclonal Antibodies to Renal Antigens,Am. J. of Pathol, 123:301-309, (May 1986).
Uemura, et al., MN/CA IX/G250 as a Potential Target for Immunotherapy of Renal Cell Carcinomas,Br J. Cancer, 81(4):741-746 (Oct. 1999).
Závada, et al., Human Tumour-Associated Cell Adhesion Protein MN/CA IX: Identification of M75 Epitope and of the Region Mediating Cell Adhesion;Br. J. Cancer, 82(11):1808-1813 (2000).
Dijk et al., “Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor in Mice with Renal-Cell Carcinoma Xenografts,”International Journal of Cancer, 56: 262-268 (1994).
Steffens et al., “Targeting of Renal Cell Carcinoma with Iodine-131-Labeled Chimeric Monoclonal Antibody G250,”Journal of Clinical Oncology, 15: 1529-1537 (1997).
Supplementary Partial European Search Report, Application No. EP 02 78 6854, in six (6) pages.
Foltz Ian
Gallo Michael L.
Gudas Jean
Handa Masahisa
Amgen Fremont Inc.
Canella Karen A.
Knobbe Martens Olson & Bear LLP
LandOfFree
Antibodies against carbonic anhydrase IX (CA IX) tumor antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against carbonic anhydrase IX (CA IX) tumor antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against carbonic anhydrase IX (CA IX) tumor antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3930159